NIH Invests $150 Million in Human-Based Research: A Strong Signal for the Future of NAMs and Organoid Technologies

The recent NIH announcement of more than $150 million in funding for human-based research methods marks one of the most significant investments to date in accelerating the adoption of New Approach Methodologies (NAMs) and reducing reliance on animal models in Europe. What stands out most is that the NIH is not only funding innovation but also investing in the critical elements required for broad adoption: standardization, validation, regulatory qualification, and data sharing.  

Which human-based models can deliver both biological relevance and reproducible, decision-ready data?  

At abc biopply AG, we believe this is where the next generation of organoid technologies will make a major impact. 
While traditional 2D cell cultures provide exceptional throughput, they are based on highly simplified biological systems that often fail to reproduce the complexity of human tissues. Conventional 3D organoid cultures add physiological relevance but usually cultivate a limited number of isolated organoids in standard plastic ware which therefore vary in size, morphology, differentiation state, and growth characteristics, creating challenges in reproducibility and cross-study comparability. 

Our proprietary 3D CoSeedis™ Humanized Multi-Organoid Technology was developed to bridge exactly this gap. Rather than relying on a few isolated organoids, the platform creates highly standardized micro-tissues composed of hundreds of communicating organoids under validated conditions. This generates robust multi-organoid statistics while maintaining the biological complexity required for translational research.  

As Europe's first fully integrated Organoid CRO, abc biopply already provides validated services for: 

✅ Drug efficacy studies 

✅ Toxicity and safety assessment 

✅ Resistance and relapse testing 

✅ Biomarker development 

✅ Oncology, neurology, hepatic, renal, obesity and other disease models 

✅ Custom-designed humanized disease models  

Organizations that can provide validated NAM platforms with clear translational value will be uniquely positioned to support this transformation. We believe abc biopply's 3D CoSeedis™ Multi-Organoid Technology can play an important role in helping researchers, biotech companies, pharma partners, and regulators accelerate the transition toward more predictive human-based drug development.  

Read more here